Tiotropium

Generic Name: Tiotropium

Brand Names: Inspiolto Respimat, Spiriva, Spiriva Respimat, Stiolto

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₂NO_₄S_₂

CAS Number: 186691-13-4

Unique Ingredient Identifier: 0EB439235F

Background: Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.

Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than ipratropium.

Tiotropium was granted FDA approval on 30 January 2004.

Indication: Tiotropium powder for inhalation is indicated for the maintenance of bronchospasm in COPD and to prevent exacerbations of COPD. A combination tiotropium and olodaterol metered inhalation spray is indicated for maintenance of COPD. A tiotropium inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 12 or more years old. A tiotropium metered inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 6 or more years old.

Associated Conditions: Asthma, Bronchitis, Bronchoconstriction, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Exacerbation of COPD

Clinical Trials

Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response

Phase 4

Not yet recruiting

Conditions: Asthma Bronchiale

Interventions: Drug: Tiotropium (Spiriva®)
Drug: Placebo

First Posted Date: 2024-11-07

Last Posted Date: 2024-11-07

Lead Sponsor: University of Saskatchewan

Target Recruit Count: 10

Registration Number: NCT06679465

Locations: 🇨🇦
University of Saskatchewan, Saskatoon, Saskatchewan, Canada

Effect of Tiotropium on Eye Findings in the Treatment of Chronic Obstructive Pulmonary Disease

Completed

Conditions: Glaucoma, Angle-Closure
Chronic Obstructive Pulmonary Disease

Interventions: Drug: Tiotropium

First Posted Date: 2024-07-29

Last Posted Date: 2024-07-29

Lead Sponsor: Giresun University

Target Recruit Count: 108

Registration Number: NCT06525051

Locations: 🇹🇷
Giresun Training and Research Hospital, Giresun, Gi̇resun, Turkey

A Trial to Assess the Bioequivalence of Tiotropium Bromide Inhalation Powder in Healthy Adult Participants Under Fasting Conditions

Phase 1

Active, not recruiting

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Spiriva®Handihaler®
Drug: Tiotropium Bromide Inhalation Powder

First Posted Date: 2024-07-05

Last Posted Date: 2024-07-05

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 186

Registration Number: NCT06487416

Locations: 🇨🇳
The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China

A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)

Phase 1

Active, not recruiting

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Tiotropium Bromide Inhalation Powder
Drug: Spiriva HandiHaler

First Posted Date: 2024-03-22

Last Posted Date: 2024-03-29

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 39

Registration Number: NCT06326671

Locations: 🇨🇳
Henan (Zhengzhou) Zhonghui Cardiovascular Hospital, Zhengzhou, Henan, China

ANTES B+ Clinical Trial

Phase 4

Recruiting

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Trelegy Ellipta 100/62.5/25Mcg Inh 30D
Drug: Brimica
Drug: Duaklir
Drug: Ultibro
Drug: Ulunar
Drug: Xoterna
Drug: Anoro
Drug: Laventair
Drug: Spiolto Respimat
Drug: Yanimo
Drug: Foradil
Drug: Broncoral
Drug: Formoterol stada
Drug: Oxis
Drug: Formatris
Drug: Formoterol Aldo
Drug: Onbrez
Drug: Oslif
Drug: Hirobriz
Drug: Striverdi
Drug: Beglan
Drug: Betamican
Drug: Inaspir
Drug: Serevent
Drug: Soltel
Drug: Eklira
Drug: Bretaris
Drug: Seebri
Drug: Tovanor
Drug: Enurev
Drug: Spiriva
Drug: Tavulus
Drug: Sirkava
Drug: Braltus
Drug: Gregal
Drug: Incruse
Drug: Rolufta

First Posted Date: 2024-02-28

Last Posted Date: 2024-03-05

Lead Sponsor: Fundacio Privada Mon Clinic Barcelona

Target Recruit Count: 1028

Registration Number: NCT06282861

Locations: 🇪🇸
Hospital Clínic Barcelona, Barcelona, Catalunya, Spain

Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule,Zephir Inhaler Device

Phase 1

Completed

Conditions: COPD

Interventions: Drug: Tiotropium 18 µg inhalation powder, hard capsule
Device: Zephir inhaler

First Posted Date: 2024-02-12

Last Posted Date: 2024-02-12

Lead Sponsor: Xiromed LLC

Target Recruit Count: 116

Registration Number: NCT06254664

Locations: 🇺🇸
Vanguard Clinical Research, LLC, Fort Myers, Florida, United States
🇺🇸
My Preferred Research LLC, Miami, Florida, United States
🇺🇸
Clintex Research Group, Miami, Florida, United States

and more 6 locations